Literature DB >> 8957218

Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A.

S Cho1, A M Duchemin, N H Neff, M Hadjiconstantinou.   

Abstract

After acute administration of the monoamine oxidase inhibitor clorgyline there is a reduction of aromatic L-amino acid decarboxylase and tyrosine hydroxylase activity in the mouse striatum. Similar responses were seen after administering the non-selective monoamine oxidase inhibitor pargyline and high, but not low, doses of the selective monoamine oxidase-B inhibitor deprenyl. Changes of tyrosine hydroxylase activity were observed only when subsaturated concentrations of the pteridine cofactor were used for the assay. The monoamine oxidase inhibitors altered the abundance of aromatic L-amino acid decarboxylase and tyrosine hydroxylase mRNA in the midbrain. Pargyline and high doses of deprenyl increased, aromatic L-amino acid decarboxylase mRNA, while clorgyline initially decreased and then increased it. All three compounds caused an early decrease of tyrosine hydroxylase mRNA. The acidic metabolites of dopamine appeared most affected by pargyline and clorgyline, supporting the notion that deamination of striatal dopamine in rodents is primarily by monoamine oxidase-A. Our results suggest, that striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase are apparently modulated via different mechanisms in response to perturbation of dopamine metabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957218     DOI: 10.1016/s0014-2999(96)00530-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Inhibition of allergic inflammation by supplementation with 5-hydroxytryptophan.

Authors:  Hiam Abdala-Valencia; Sergejs Berdnikovs; Christine A McCary; Daniela Urick; Riti Mahadevia; Michelle E Marchese; Kelsey Swartz; Lakiea Wright; Gökhan M Mutlu; Joan M Cook-Mills
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-07-27       Impact factor: 5.464

2.  Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.

Authors:  David S Goldstein; Yunden Jinsmaa; Patti Sullivan; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

Review 3.  Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders.

Authors:  J Ng; S J R Heales; M A Kurian
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.